The Filing Desk

Cellebrite DI

CLBT · Nasdaq · Information Technology · Financials, fiscal 2019 to 2025

CLBT · Last close · November 19, 2026
$11.32

Cellebrite DI's revenue rose 18.6% to $476 million in fiscal 2025. Its operating margin was 14.0%, down from 14.2% a year earlier. Free cash flow was $160 million, up 29.7%. The diluted share count rose 19.3%.

Cellebrite DI Ltd. Latest fiscal year ended December 31, 2025 20-F filed March 3, 2026 · 0001628280-26-013790 Updated
Revenue
$476M
18.6%
Operating margin
14.0%
0.2 pts
Net income
$78M
 
Free cash flow
$160M
29.7%
Return on equity
19.1%
172.0 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Cellebrite DI is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What Cellebrite DI does

Cellebrite is an Israeli software company. Its tools help investigators get data off mobile phones and other digital sources, decode it, analyze it and manage it as evidence. It has built them over nearly 20 years of work on phones, including their hardware, firmware and operating systems.

Its customers are mostly law enforcement agencies, which use the software in cases such as child exploitation, homicide, organized crime, human trafficking and financial crime. Defense and intelligence agencies use it for border security and counter-terrorism. Companies use it for corporate investigations, eDiscovery (collecting digital records for legal cases) and incident response, and to test mobile apps.

Cellebrite sells its software mainly through annual and multi-year subscriptions. It tracks annual recurring revenue, the yearly value of those subscriptions, and says it has seen that figure and customer retention grow. Its results depend on customers renewing and buying more, and on government agencies continuing to buy.

Its biggest risks, as it describes them

  • It must keep building new, technically advanced products, or its revenue may suffer.
  • Its revenue falls if law enforcement and other government agencies stop buying or using its tools.
  • Errors, failures or bugs in its software could hurt its results and growth.
  • It licenses technology from third parties and could lose those licenses.
  • It faces intense competition and industry consolidation that could add to price pressure.
From Cellebrite DI's annual report on Form 20-F, filed March 3, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2021 to 2025, earnings per share fell 8.4% a year and net income grew 2.3% a year, as new shares raised the share count by 55% and diluted each share's earnings.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments146132228294276
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio1.5x1.4x1.7x1.9x1.6x
Quick ratio1.4x1.4x1.6x1.9x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 4049.9%54.2%52.3%
Altman Z''3.293.362.73
Accruals ratio−39.1%−67.9%−11.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't risePassFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Cellebrite DI side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Cellebrite DIFY2518.6%14.0%33.7%———
StrategyFY253.0%−1,140.8%−15.8%−11.4%—4Compare
Life360FY2531.8%3.9%17.7%6.7%−5.7x5Compare
XunleiFY2542.5%1.4%5.9%1.1%−15.2x5Compare
PagerDutyFY265.4%1.2%22.7%4.7%−2.6x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue172195246271325401476
Revenue growth—13.4%26.3%9.9%20.1%23.4%18.6%
Gross profit136157204220272339400
Research and development475466818498114
Operating income−29141335766
Net income−2671121−81−28378
Diluted EPS (US$)−0.08−0.080.440.59−0.43−1.350.31
Diluted shares (millions)122124162195190210250
Cash flow
Cash from operations16663621102132174
Capital expenditure66575913
Free cash flow1060311497124160
Dividends paid25101000000
Share buybacks1000000
Acquisitions01520003148
Stock-based compensation137614193145
Balance sheet at fiscal year end
Cash and short-term investments82134146132228294276
Debt incl. finance leases———————
Total assets—364340403533691939
Total liabilities—199413329499354454
Shareholders' equity5964−737434336484
Margins and ratios
Gross margin79.2%80.6%82.7%81.2%83.6%84.4%84.2%
Operating margin−0.9%4.7%5.6%0.4%10.2%14.2%14.0%
Net margin−1.1%3.0%29.0%44.6%−24.9%−70.5%16.5%
Free cash flow margin5.8%30.9%12.6%5.0%29.8%30.8%33.7%
Rule of 40 (growth + FCF margin)—44.4%38.9%15.0%49.9%54.2%52.3%
Return on capital———————
Return on equity————−150.1%−152.9%19.1%
Return on assets——20.3%32.5%−17.3%−46.3%9.6%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cellebrite DI's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cellebrite DI.